A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of Palbociclib

Phase 1

Completed

• Conditions: Healthy, Hepatic Insufficiency
• Interventions: Drug: Palbociclib 75 mg Capsule

• Registration Number: NCT02334800
• Lead Sponsor: Pfizer

Brief Summary

This is a phase 1 study to describe the plasma pharmacokinetics of a single oral 75mg dose of palbociclib administered to healthy volunteers, and subjects with mild, moderate, and severely impaired hepatic function.

Detailed Description

This is a 4-cohort single period study. The four cohorts will consist of healthy volunteers, and subjects with mild, moderate, and severely impaired hepatic function. Each cohort will receive the same treatment consisting of a single oral 75mg dose of palbociclib administered with food. Serial PK samples will be drawn up to 120 hours post dose for the cohort consisting of healthy volunteers, and will continue until up to 192 hours post-dose for the cohorts of hepatic impairment subjects.

Study Timeline

• Study First Submitted: 2015-01-06
• Study First Submitted QC: 2015-01-06
• Study First Posted: 2015-01-08
• Study Start: 2015-03-31
• Primary Completion: 2016-10-09
• Study Completion: 2016-10-09
• Status Verified: 2017-05
• Results First Submitted: 2017-06-08
• Results First Submitted QC: 2017-06-08
• Last Update Submitted: 2017-06-08
• Results First Posted: 2018-01-24
• Last Update Posted: 2018-01-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 28

Inclusion Criteria

• Body Mass Index (BMI) of 18 to 40 kg/m2; and a total body weight >50 kg (110 lbs)
• Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study
• Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures

Exclusion Criteria

• Any condition possibly affecting drug absorption (eg, gastrectomy)
• A positive urine drug screen
• Pregnant female subjects; breastfeeding female subjects; female subjects of childbearing potential; male subjects with partners currently pregnant; male subjects of childbearing potential who are unwilling or unable to use a highly effective method of contraception for the duration of the study and for 90 days after the last dose of investigational product
• History of sensitivity to heparin or heparin-induced thrombocytopenia
• Blood donation of approximately 1 pint (500 mL) or more within 56 days prior to dosing
• Unwilling or unable to comply with the Lifestyle Guidelines described in this protocol
• Use of tobacco or nicotine products in excess of 5 cigarettes per day (or equivalent)
• History of sensitivity to palbociclib

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Healthy Volunteers	Palbociclib 75 mg Capsule	Cohort of Healthy Volunteers
Mild Hepatic Impairment	Palbociclib 75 mg Capsule	Cohort of mild hepatic impairment subjects meeting the criteria for Child-Pugh Class A
Moderate Hepatic Impairment	Palbociclib 75 mg Capsule	Cohort of moderate hepatic impairment subjects meeting the criteria for Child-Pugh Class B
Severe Hepatic Impairment	Palbociclib 75 mg Capsule	Cohort of severe hepatic impairment subjects meeting the criteria for Child-Pugh Class C

Primary Outcome Measures

Name	Time	Method
Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinite Time (AUCinf)	Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.	AUCinf is area under the plasma concentration time curve from time 0 extrapolated infinite time. It is calculated as AUClast + (Clast/kel), where AUClast is area under the concentration-time curve from time 0 to the time of the last quantifiable concentration, Clast is the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Maximum Plasma Concentration (Cmax)	Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.	Cmax is maximum plasma concentration. It is observed directly from data.

Secondary Outcome Measures

Name	Time	Method
Unbound AUCinf (AUCinf,u)	Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.	AUCinf,u is unbound AUCinf, where AUCinf is area under the concentration-time curve from time 0 extrapolated to infinite time. It is obtained by fu\*AUCinf, where fu is the fraction of unbound drug in plasma.
Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast)	Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.	AUClast is area under the plasma concentration time curve from time 0 to time of last quantifiable concentration. It is obtained from linear/log trapezoidal method.
Unbound AUClast (AUClast,u)	Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.	AUClast,u is unbound AUClast, where AUClast is area under the concentration-time curve from time 0 to the time of the last quantifiable concentration. It is obtained by fu\*AUClast, where fu is the fraction of unbound drug in plasma.
Apparent Clearance After Oral Dose(CL/F)	Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.	Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance is obtained by dose/AUCinf, where AUCinf is the area under the concentration-time curve from time 0 extrapolated to infinite time.
Unbound CL/F (CLu/F)	Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.	CLu/F is unbound CL/F, where CL/F is apparent clearance after oral dose. It is obtained by dose/AUCinf,u, where AUCinf,u is unbound AUCinf (area under the concentration-time curve from time 0 extrapolated to infinite time).
Unbound Cmax (Cmax,u)	Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.	Cmax,u is unbound Cmax, where Cmax is maximum plasma concentration. It is obtained by fu\*Cmax, where fu is fraction of unbound drug in plasma.
Fraction of Unbound Drug in Plasma (fu)	Eight (8) hours post-dose.	Fu is the fraction of unbound drug in plasma. It is obtained from measurement of protein binding.
Terminal Half-Life (t1/2)	Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.	T1/2 is terminal half-life. It is obtained by loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Time for Cmax (Tmax)	Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.	Tmax is time for maximum plasma concentration. It is observed directly from data as time of first occurrence of maximum plasma concentration.
Apparent Volunm of Distribution After Oral Dose (Vz/F)	pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.	Vz/F is the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. It is influenced by the fraction absorbed. It is obtained by dose/(AUCinf•kel), where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve, and AUCinf is the area under the concentration-time curve from time 0 extrapolated to infinite time.
Unbound Vz/F (Vz,u/F)	Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.	Vz,u/F is unbound Vz/F, where Vz/F is apparent volume of distribution after oral dose. It is obtained by dose/(AUCinf,u\*kel), where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve, and AUCinf,u is unbound AUCinf (area under the concentration-time curve from time 0 extrapolated to infinite time).
Number of Participants With Treatment Emergent Adverse Events	Adverse events were recorded on the Case Report Form from the time the participant had taken at least 1 dose of palbociclib through the participant's last visit.	An adverse event is any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Any events occurring following start of treatment or increasing in severity are counted as treatment emergent. Relatedness to palbociclib is assessed by the investigator (Yes/No). Participants with multiple occurrences of an adverse event within a category are counted once within the category.
Number of Participants With Treatment Emergent Serious Adverse Events	The active reporting period for serious adverse events began from the time that the participant provided informed consent through and including 28 calendar days after the last administration of palbociclib.	A serious adverse event is any untoward medical occurrence at any dose that resulted in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; or results in congenital anomaly/birth defect. Any events occurring following start of treatment or increasing in severity are counted as treatment emergent. Relatedness to palbociclib is assessed by the investigator (Yes/No).
Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)	Baseline up to Day 6 for Cohort 1 and to Day 9 for Cohorts 2, 3, and 4, inclusive of baseline values.	Laboratory tests included tests that were performed under the categories of hematology, chemistry, urinalysis, other, and additional tests needed for Hy's law.
Number of Participants With Physical Examination Test Abnormalities (Change From Prior Visit)	Baseline up to Day 6 for Cohort 1 and to Day 9 for Cohorts 2, 3, and 4.	A full physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. The limited or abbreviated physical examination was focused on general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms.
Number of Participants With Post Baseline Vital Signs Values Meeting Categorical Summarization Criteria	Baseline up to Day 6 for Cohort 1 and to Day 9 for Cohorts 2, 3, and 4, not including baseline values.	The number of participants with post baseline vital signs values meeting the following criteria was reported: A. absolute value of supine systolic blood pressure less than (\<) 90 mmHg; B. absolute value of diastolic blood pressure \<50 mmHg; C. absolute value of supine pulse rate \<40 bmp; D. absolute value of supine pulse rate larger than (\>) 120 bmp; E. maximum increase from baseline in supine systolic blood pressure larger than and equal to (\>=) 30 mmHg; F. maximum increase from baseline in supine diastolic blood pressure \>=20 mmHg; G. maximum decrease from baseline in supine systolic blood pressure \>=30 mmHg; and H. maximum decrease from baseline in supine diastolic blood pressure \>=20 mmHg.
Number of Participants With Post Baseline Electrocardiogram Values Meeting Categorical Summarization Criteria (Maximum Absolute Values)	Baseline up to Day 6 for Cohort 1 and to Day 9 for Cohorts 2, 3, and 4, not including baseline values.	Maximum absolute values of post baseline electrocardiogram were summarized for PR interval, QRS complex, QT interval, QTcB (QT interval calculated using Bazett's correction factor), and QTcF (QT interval calculated using Fridericia's correction factor). The number of participants with maximum absolute values of post baseline electrocardiogram meeting the following criteria was reported: (1) PR interval \>=300 msec; (2) QRS complex \>=140 msec; (3) QT interval 450 to \<480 msec; (4) QT interval 480 to \<500 msec; (5) QT interval \>= 500 msec; (6) QTcB 450 to \<480 msec; (7) QTcB 480 to \<500 msec; (8) QTcB \>= 500 msec; (9) QTcF 450 to \<480 msec; (10) QTcF 480 to \<500 msec; and (11) QTcF \>=500 msec. Seven (7) participants in each cohort were evaluated for electrocardiogram tests except that 6 participants in the moderate hepatic impairment cohort (Cohort 3) were evaluated for PR interval.
Number of Participants With Post Baseline Electrocardiogram Values Meeting Categorical Summarization Criteria (Maximum Increase From Baseline)	Baseline up to Day 6 for Cohort 1 and to Day 9 for Cohorts 2, 3, and 4, not including baseline values.	Maximum increases from baseline for post baseline electrocardiogram values were summarized for PR interval, QRS complex, QT interval, QTcB (QT interval calculated using Bazett's correction factor), and QTcF (QT interval calculated using Fridericia's correction factor). The number of participants with maximum increase from baseline for post baseline electrocardiogram values meeting the following criteria was reported: (1) percent change of PR interval \>=25/50%; (2) percent change of QRS complex \>=50%; (3) QT interval 30 to \<60 msec; (4) QT interval \>= 60 msec; (5) QTcB 30 to \<60 msec; (6) QTcB \>= 60 msec; (7) QTcF 30 to \<60 msec; and (8) QTcF \>= 60 msec. Seven (7) participants in each cohort were evaluated for electrocardiogram tests except that 6 participants in the moderate hepatic impairment cohort (Cohort 3) were evaluated for PR interval.
Number of Participants With Concomitant Medications	From screening through and including Day 6 for Cohort 1, and from screening through and including Day 9 for Cohorts 2, 3, and 4.	Treatments taken after the first dose of study treatment were documented as concomitant treatments.

Trial Locations

Locations (2)

Orlando Clinical Research Center; 🇺🇸 Orlando, Florida, United States

Weston Diagnostics (Ultrasound Facility); 🇺🇸 Orlando, Florida, United States